The global uterine manipulation devices market size was valued at USD 269.06 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2030. The rising prevalence of diseases related to female reproductive organs, the increase in the adoption of minimally invasive or noninvasive procedures, and technological advancements are among the major factors driving the market. The COVID-19 pandemic affected significant aspects of various companies, such as product demand, operations, supply chain, distribution systems, and the ability to research and develop new products. Almost all the companies were negatively impacted by reduced procedure volume due to the pandemic as all hospital resources were being diverted to combat the disease.
Nowadays, minimally invasive and noninvasive surgeries are gaining popularity owing to the reduced risk associated with these procedures. Smaller incisions decrease postoperative pain and facilitate speedy recovery, leading to the high adoption of these procedures. For instance, laparoscopic or robotic-assisted hysterectomy is a less invasive surgical technique performed to remove the uterus. A small incision is made in the lower abdomen and a miniature camera and small, specialized instruments are inserted and used for the removal process. Thus, the risk of blood loss and infection is lower in the case of minimally invasive procedures than in open surgeries. Thus, an increase in patient preference for noninvasive or minimally invasive treatment and the benefits offered by these techniques are expected to boost market growth at a significant rate during the forecast period.
The high prevalence of disorders related to the female reproductive system in developed and developing countries has driven the launch of technologically advanced products in the market. Some of the key players operating in this market are CooperSurgical, Inc.; Stryker Corporation; KARL STORZ GmbH; CONMED Corporation; and Ethicon, Inc. Technological advancements such as the introduction of laparoscopic or robotic-assisted hysterectomy procedures have led to the adoption of incision-less surgery with no or minimal side effects. As compared to open abdominal hysterectomy, robotic-assisted hysterectomy provides advantages such as less blood loss, fewer complications, and faster return to normal activities. Thus, the use of robots, owing to their several advantages over conventional laparoscopy (open surgery), has been widely accepted and incorporated in the field of reproductive surgery. This is expected to be a high impact rendering driver of the market.
In addition, key companies operating in the uterine manipulation devices market for uterine manipulation devices are adopting strategies such as mergers & acquisitions, and partnerships, to strengthen their product portfolios, and manufacturing capacities, and provide competitive diversity. For instance, in January 2020, the research study titled "Ultrasound Imaging of Acquired Myometrial Pseudoaneurysm: The Role of Manipulators as an Unusual Cause during Laparoscopic Surgery" demonstrated favorable outcomes for the ClearView Uterine Manipulator with a 7 cm tip in obstetric surgery. The study concluded that the use of these manipulators during surgical procedures is deemed safe and reliable. These findings contribute to the validation of the ClearView Uterine Manipulator as a trusted and effective tool for gynecological surgeries, positioning it as an asset in the market.
The Total Laparoscopy Hysterectomy (TLH) segment accounted for the largest revenue share of 38.5% in 2022. TLH is performed for treating conditions such as fibroids, pelvic pain, painful or heavy menstrual periods, pre-cancer or cancer in the uterus, endometriosis or adenomyosis, or prolapse. It is an in-patient procedure and is usually performed under general anesthetic and patients spend only a night in the hospital. It involves 2-4 weeks of recovery at home. Moreover, the recovery period associated with major abdominal hysterectomy is longer in comparison with laparoscopic surgery, which is leading to an increase in the preference for laparoscopic surgery. Thus, the segment is expected to witness rapid growth over the forecast period.
The Laparoscopic Supracervical Hysterectomy (LSH)segment is expected to grow at the fastest CAGR of 8.5% during the forecast period. LSH is a minimally invasive procedure, which involves removing a uterus and leaving the cervix in place. It is performed to treat conditions or complications of the uterus such as endometriosis, fibroids, abnormal vaginal bleeding, pelvic pain, and infection in ovaries/fallopian tubes. It is a partial hysterectomy that removes only the diseased uterus and preserves the cervix, and often ovaries, thus resulting in less pain, fewer adhesions, less technical difficulty, and quicker recovery than open surgery.
The hospitals segment accounted for the largest revenue share of 59.3% in 2022 and is expected to expand at a CAGR of 8.0% over the forecast period. The growth of this segment can mainly be attributed to an increase in the number of patients suffering from various gynecological conditions and a consequent rise in the number of surgical procedures. Hospitals offer superior care to patients and provide reimbursements for certain procedures, which further contributes to segment growth. Furthermore, hospitals are currently advancing in terms of technology. Technologically advanced devices are being used extensively in hospitals to provide better treatment. These devices are not only simplifying treatment procedures but also providing better, faster, and more accurate results.
The ambulatory surgery centers segment is expected to register the fastest CAGR of 8.5% over the forecast period. High preference for outpatient surgeries, increase in the adoption of minimally invasive surgeries, and cost-effectiveness of ambulatory surgery center-based laparoscopic procedures are among the key factors responsible for the lucrative growth of this segment. The lower risk of post-surgical complications in minimally invasive laparoscopic surgery is expected to increase the demand for ambulatory surgery centers. They offer several advantages to patients including shorter procedure time and same-day discharge as compared to hospitals. Most intra-abdominal procedures can now be performed laparoscopically at ambulatory surgery centers as these are less invasive. Surgeries at ambulatory surgery centers not only have shorter stay duration but are also more affordable than inpatient procedures, which reduces patient expenditure. Thus, owing to the abovementioned factors, the ambulatory surgery centers segment is likely to witness rapid growth during the forecast period.
North America dominated the market and accounted for the largest revenue share of 35.2% in 2022. This is owing to the increasing number of gynecology-related surgical procedures/hospital visits, the presence of well-established healthcare infrastructure, favorable reimbursement policies, and supportive regulatory reforms in the healthcare sector. According to CMS, healthcare spending in the U.S. increased by 4.6% and reached USD 3.8 trillion in 2019, accounting for approximately 17.7% of GDP. The national health spending is expected to grow at an annual rate of 5.4% from 2019 to 2028, to reach USD 6.2 trillion by the year 2028. The ease of access to healthcare technologies and the presence of strong distribution channels are also driving the adoption of uterine manipulation devices in the region.
In March 2022, the ENDOMETRIOSIS FOUNDATION OF AMERICA organized multiple virtual events throughout several weekends to commemorate Patient Day. The events focused on topics such as peritoneal endometriosis, pain management, and comprehensive treatment options for severe and debilitating endometriosis. This platform was specifically designed to facilitate patient networking, knowledge sharing, and the exchange of personal experiences. It serves as a valuable resource for individuals to connect, gain insights into the disease, and contribute to the collective understanding of endometriosis in the business community.
Asia Pacific is expected to expand at the fastest CAGR of 6.5% during the forecast period. The presence of a large patient pool and the growing need for technologically advanced and cost-effective healthcare solutions are among the factors expected to present significant growth opportunities for the market. Moreover, an increase in the number of clinical trials and high R&D investments by global market players to enter untapped markets in the Asia Pacific region owing to low-cost services are high impact rendering drivers of the market. In addition, an increase in the number of hospitalizations and rapid advancements in the clinical development framework of developing economies are aiding market growth in this region.
Key players are involved in adopting strategies such as mergers & acquisitions, partnerships, and new product launches to strengthen their foothold in the market. For instance, in February 2021, CooperSurgical Inc. acquired AEGEA Medical. The acquisition is expected to help the company expand its product portfolio in women's healthcare. In another instance, in October 2020, LABORIE Medical Technologies partnered with Urotronic. The partnership would expand the use of minimally invasive treatments and advance outcomes for patients suffering from urological disorders. Some prominent players in the global uterine manipulation devices market include:
Conkin Surgical Instruments Ltd.
Johnson and Johnson
B. Braun Medical Ltd.
KARL STORZ GmbH & Co. KG
RUDOLF Medical GmbH + Co. KG
LiNA Medical ApS
Richard Wolf GmbH
Utah Medical Products, Inc.
Clinical Innovations, LLC
The O.R. Company (Symmetry Surgical Inc.)
LSI Solutions, Inc.
Market size value in 2023
USD 283.2 million
Revenue forecast in 2030
USD 421.7 million
CAGR of 5.9% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Application, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Conkin Surgical Instruments Ltd.; Johnson and Johnson; CooperSurgical, Inc.; B. Braun Medical Ltd., KARL STORZ GmbH & Co. KG; CONMED Corporation; RUDOLF Medical GmbH + Co. KG; LiNA Medical ApS; Richard Wolf GmbH; Utah Medical Products, Inc.; Purple Surgical; Clinical Innovations, LLC; Bissinger Medizintechnik; The O.R. Company (Symmetry Surgical Inc.); LSI Solutions, Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global uterine manipulation devices market based on application, end-use, and region:
Application Outlook (Revenue in USD Million, 2018 - 2030)
Total Laparoscopy Hysterectomy (TLH)
Laparoscopic Supracervical Hysterectomy (LSH)
Laparoscopically Assisted Vaginal Hysterectomy (LAVH)
End-use Outlook (Revenue in USD Million, 2018 - 2030)
Ambulatory Surgery Centers (ASCs)
Regional Outlook (Revenue in USD Million, 2018 - 2030)
Middle East and Africa
b. The global uterine manipulation devices market size was estimated at USD 269.06 million in 2022 and is expected to reach USD 283.2 million in 2023.
b. The global uterine manipulation devices market is expected to grow at a compound annual growth rate of 5.9% from 2023 to 2030 to reach USD 421.7 million by 2030.
b. North America dominated the uterine manipulation devices market with a share of 35.2% in 2022. This is attributable to the presence of the key market players, and various awareness initiatives by the government and non-government organizations.
b. Some of the key players operating in the uterine manipulation devices market include Conkin Surgical Instruments Ltd., Johnson and Johnson, CooperSurgical, Inc., B. Braun Medical Ltd., KARL STORZ GmbH & Co. KG, CONMED Corporation, RUDOLF Medical GmbH + Co. KG, LiNA Medical ApS, Richard Wolf GmbH, Utah Medical Products, Inc., Purple Surgical, Clinical Innovations, LLC, Bissinger Medizintechnik, The O.R. Company (Symmetry Surgical Inc.) and LSI Solutions, Inc.
b. Key factors that are driving the uterine manipulation devices market growth include rising prevalence of diseases related to female reproductive organs, increase in the adoption of minimally invasive or noninvasive procedures and technological advancements.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."